Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Johnson & Johnson (GB:0R34)
LSE:0R34
Johnson & Johnson (0R34) Share Price & Analysis
58 Followers
0R34 Stock Chart & Stats
Day’s Range$146.01 - $147.22
52-Week Range― - ―
Previous Close$146.6
Volume6.99K
Average Volume (3M)N/A
Market Cap
$352.17B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
Jul 16, 2024EPS Estimate
$2.72Next Dividend Ex-Date
May 20, 2024Dividend Yield3.24%
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$174.62Price Target Upside19.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
Johnson & Johnson News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceJNJ's diverse operations and recent financial performance, including a revenue growth of ~4% organic and an EPS beat, demonstrate the company's stability and potential for growth.
Product PipelinePipeline progression with drugs like nipocalimab and JNJ-2113, and recent approvals such as Cartitude-4, are expected to fuel revenue growth and could drive positive investor sentiment.
Stock UpgradeAnalyst upgrades JNJ to Buy citing asymmetric risk and attractive upside potential with a target price raised to USD170, indicating a significant upside.
Bears Say
Financial PerformanceMedTech margins (adj income before tax) declined from 24.5% to 15.5%—a 9-point drop.
Legal ChallengesTalc litigation is expected to continue being an overhang for the company in the near-term.
Product SalesCarvykti sales were disappointing, showing a decrease and failing to meet the expected sequential growth.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.19% Insiders
18.82% Mutual Funds
22.92% Other Institutional Investors
58.06% Public Companies and
Individual Investors
0R34 FAQ
What was Johnson & Johnson’s price range in the past 12 months?
Currently, no data Available
What is Johnson & Johnson’s market cap?
Currently, no data Available
When is Johnson & Johnson’s upcoming earnings report date?
Johnson & Johnson’s upcoming earnings report date is Jul 16, 2024 which is in 76 days.
How were Johnson & Johnson’s earnings last quarter?
Johnson & Johnson released its earnings results on Apr 16, 2024. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.656 by $0.054.
Is Johnson & Johnson overvalued?
According to Wall Street analysts Johnson & Johnson’s price is currently Undervalued.
Does Johnson & Johnson pay dividends?
Johnson & Johnson pays a Quarterly dividend of $1.24 which represents an annual dividend yield of 3.24%. See more information on Johnson & Johnson dividends here
What is Johnson & Johnson’s EPS estimate?
Johnson & Johnson’s EPS estimate is $2.72.
How many shares outstanding does Johnson & Johnson have?
Currently, no data Available
What happened to Johnson & Johnson’s price movement after its last earnings report?
Johnson & Johnson reported an EPS of $2.71 in its last earnings report, beating expectations of $2.656. Following the earnings report the stock price went down -2.552%.
Which hedge fund is a major shareholder of Johnson & Johnson?
Among the largest hedge funds holding Johnson & Johnson’s share is Fisher Asset Management LLC. It holds Johnson & Johnson’s shares valued at 997M.
---
Johnson & Johnson Stock Smart Score
Company Description
Johnson & Johnson
Johnson & Johnson provides healthcare products across three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.
---
0R34 Company Deck
---
0R34 Earnings Call
Q1 2024
0:00 / 0:00
---
0R34 Sales Breakdown
64.30% Innovative Medicine
35.70% MedTech
---
0R34 Stock 12 Months Forecast
Average Price Target
$174.62
▲(19.11% Upside)
Technical Analysis
Best Analysts Covering 0R34
1 Year
1 Year Success Rate
21/22 ratings generated profit
1 Year Average Return
+9.42%
upgraded a buy rating 5 months ago
Copying Danielle Antalffy's trades and holding each position for 1 Year would result in 95.45% of your transactions generating a profit, with an average return of +9.42% per trade.
---